British Medical Journal retracts Prozac report

Share this article:

The British Medical Journal (BMJ) has published a retraction of its allegations that Eli Lilly hid documents linking use of its antidepressant Prozac with a heightened risk of suicide.
BMJ said the documents went missing during a 1994 lawsuit, in an article published earlier this month. The suit against Lilly involved a gunman who killed eight people in a workplace shooting in Kentucky and had been prescribed Prozac.
"As a result of the investigation, it is clear that these documents did not go missing," the BMJ retraction said. "The BMJ accepts that Eli Lilly acted properly in relation to the disclosure of these documents in these claims. The BMJ is happy to set the record straight and to apologize to Eli Lilly for this statement, which we now retract, but which we published in good faith."
The apology and retraction, which is available in this week's online and bound BMJ edition, references the journal's investigation into these documents after receiving a complaint from Lilly.
"We were disturbed by the initial BMJ article that inaccurately reported about Prozac and made negative inferences regarding our company's conduct," said Eli Lilly chief executive Sidney Taurel. "The apology and retraction is an important step in gaining closure on this unfortunate event . . . We accept the apology and retraction with the understanding that both our organizations are committed to providing doctors and patients with accurate information about medications."

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.